Peptide Antibiotics Global Market Report 2026

Peptide antibiotics are antibiotics composed of peptides, with their antibacterial action primarily driven by the physical disruption of bacterial cell membranes. These antibiotics penetrate bacterial membranes, accumulate inside the cells, and subsequently interfere with essential bacterial functions.

The primary types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics act by destroying or modifying the drug, altering the drug target, reducing or increasing drug uptake, or replacing a metabolic pathway as the drug's target. Ribosomally synthesized peptide antibiotics are antimicrobial peptides produced by ribosomes and are generated by nearly all forms of life, ranging from bacteria to plants and animals. Common peptide antibiotic drugs include daptomycin, dalbavancin, telavancin, and others, which are used to treat conditions such as skin infections, hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), bloodstream infections, and other diseases. Peptide antibiotics are utilized and distributed through hospitals, homecare settings, specialty clinics, and other distribution channels.

Tariffs have impacted the peptide antibiotics market by increasing import costs for raw materials and specialized manufacturing equipment, leading to higher production expenses. The ribosomal and non-ribosomal synthesized peptide antibiotics segments are particularly affected, especially in regions like North America and Europe that rely on global supply chains. While some local manufacturers may benefit from protection against foreign competition, overall, tariffs are creating cost pressures that encourage investments in domestic production and supply chain diversification.

The peptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide antibiotics market size has grown strongly in recent years. It will grow from $5.77 billion in 2025 to $6.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rise of antibiotic-resistant bacterial strains, increased hospital-acquired infection rates, advancements in peptide synthesis technologies, growing clinical research in infectious diseases, government funding for antibiotic R&D.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $9.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of multi-drug resistant infections, expansion of global healthcare infrastructure, technological advancements in peptide delivery systems, increasing collaborations with cdmos, rising awareness and adoption of precision medicine approaches. Major trends in the forecast period include rising demand for multi-drug resistant (mdr) infection solutions, expansion of peptide antibiotics in hospital-acquired infections, growth of contract manufacturing and cdmo collaborations, increasing adoption of personalized and targeted antibiotic therapies, focus on peptide antibiotics with reduced toxicity and side effects.

The growing prevalence of various infectious diseases is expected to drive the growth of the peptide antibiotics market. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, fungi, parasites, and others. Key factors contributing to the rise in infectious diseases include rapid urbanization, climate change, and an increased risk of disease emergence, among others, which have led to higher demand for peptide antibiotics. Peptide antibiotics exert their antibacterial effects by physically disrupting bacterial cell membranes. For example, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, dengue cases in the Americas had already exceeded seven million by April 2024, significantly higher than the 4.6 million cases recorded throughout 2023. Therefore, the rising incidence of infectious diseases is contributing to the growth of the peptide antibiotics market.

A rise in the prevalence of chronic diseases is anticipated to drive the growth of the peptide antibiotics market. Chronic diseases are conditions that persist for a year or longer, require continuous medical management, and restrict daily activities. The growing burden of chronic illnesses is attributed to factors such as increased tobacco use, unhealthy diets, lack of physical activity, excessive alcohol consumption, and other lifestyle-related causes. Peptide antibiotics are utilized in the treatment of chronic diseases by delivering the medication directly to the targeted area. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Hence, the rising prevalence of chronic diseases is contributing to the growth of the peptide antibiotics market.

Major companies operating in the peptide antibiotics market are introducing generic versions to offer more affordable treatment options for patients. Generic peptide antibiotics are lower-cost, off-patent alternatives to branded peptide-based antibiotics and are used to treat a range of bacterial infections. For example, in July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its product portfolio by launching a generic version of Daptomycin for Injection. Daptomycin for Injection is a peptide antibiotic classified as a cyclic lipopeptide and is produced through a non-ribosomal synthesis process. The generic formulation is available in 350 mg and 500 mg strengths and is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients as well as pediatric patients aged 1 to 17 years.

Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.

North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Antibiotics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Ribosomal Synthesized Peptide Antibiotics; Non-Ribosomal Synthesized Peptide Antibiotics
• 2) By Drugs: Daptomycin; Dalbavancin; Telavancin; Other Drugs
• 3) By Disease Outlook: Skin Infection; HABP Or VABP; Blood Stream Infection; Other Diseases
• 4) By Distribution Channel: Hospitals; Homecare; Specialty Clinics; Other Distribution Channels
• Subsegments:
• 1) By Ribosomal Synthesized Peptide Antibiotics: Aminoglycosides; Macrolides; Tetracyclines; Lincosamides
• 2) By Non-Ribosomal Synthesized Peptide Antibiotics: Bacitracins; Vancomycin; Polymyxins; Cyclic Lipopeptides
• Companies Mentioned: Eli Lilly and Company; GlaxoSmithKline plc; Novartis AG; Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sandoz International GmbH; Xellia APS; Johnson & Johnson Inc.; AstraZeneca PLC; Bayer AG; Bristol-Myers Squibb Company; Lupin Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Torrent Pharmaceuticals Ltd.; Wockhardt Ltd.; Zydus Lifesciences Limited; Alkem Laboratories Limited; Allecra Therapeutics GmbH; Basilea Pharmaceutica Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.